Question follow-through · 88844
NHS: Drugs
To ask the Secretary of State for Science, Innovation and Technology, what steps she is taking with the Secretary of State for Health and Social Care to ensure that funding for newly licensed medicines results in improved patient outcomes.
About this written question
A written question asks a government minister for information in writing. Parliament publishes the question and any answer.
- Answering body
- Department for Science, Innovation and Technology
- Tabled
- 10 Nov 2025
- Target answer date
- 12 Nov 2025
- Answer
- 18 Nov 2025 · 8 calendar days after tabling
Elapsed calendar days describe the record timeline, not whether Parliament considers an answer on time.
Votes on this topic
- Terminally Ill Adults (End of Life) Bill: Second Reading · 11 Sept 2026
- Health Bill: Report Stage: Amendment 1 · 8 Sept 2026
- Health Bill: Report Stage: New Clause 143 · 8 Sept 2026
These Commons divisions share a topic label. The question did not necessarily lead to a vote.
Recorded timeline
10 Nov 2025
Question tabled
To ask the Secretary of State for Science, Innovation and Technology, what steps she is taking with the Secretary of State for Health and Social Care to ensure that funding for newly licensed medicines results in improved patient outcomes.
12 Nov 2025
Target answer date
Date supplied by the official written-questions record.
18 Nov 2025
Answer published
The Department for Science, Innovation and Technology works closely with the Department of Health and Social Care to implement the Life Sciences Sector Plan, which seeks to improve patient outcomes by driving health innovation in England.The National Inst...
Official data retrieved 28 Sept 2026.
Later records
Possible follow-up questions
Strong links require the same MP, department and exact heading. Other same-department questions are shown as unreviewed candidates, not as confirmed follow-ups. No debate link is asserted unless a stable source relationship exists.
No later same-department questions indexed.
This is an absence in covered public data, not evidence that no follow-up occurred elsewhere.